Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRI Technique for Gene Mapping

By Biotechdaily staff writers
Posted on 21 Jul 2005
A new study demonstrates that an iron-storage molecule in the cell can function as a sophisticated tool for mapping gene expression. More...
Gene therapy in the near future may utilize a method in which noninvasive magnetic resonance imaging (MRI) is used to monitor this molecule.

The study was conducted in the biologic regulation department of the Weizmann Institute of Science (Rehovot, Israel). The investigators developed the ability of the iron-bearing ferritin molecule to be utilized as a kind of a gene "spy” by engineering genetic adaptations to cells. This approach made ferritin sensitive to tetracycline (TET), a traditional antibiotic, so that when TET is present, the ferritin is inactivated and when TET is absent, ferritin in activated. Tumor cells with modified ferritin were inserted into living mice and then tracked with MRI scanning. The scientists suppressed the expression of ferritin in the inserted cells by administering TET to the mice. When they stopping giving TET, the ferritin was "turned on,” triggering ferritin molecules to increase their numbers, thus causing an increase in iron uptake within the tumor cells. The difference between the iron content in these and in the healthy surrounding cells was visualized on the MRI scans (which are sensitive to magnetic particles such as iron), accurately detecting the genetically engineered cells.

The advantage of this noninvasive method is that cells are visible using MRI without the need for an additional contrast agent. This technique has significant potential for tracking the progress of gene therapy, including that used to reactivate the body's manufacturing of insulin in the treatment of diabetes, because these genes can be "tagged” before injecting. Therapeutic genes can then be monitored by MRI scanning to make sure the target is reached and the desired activations occur.

"The use of ferritin as a reporter gene would be particularly beneficial in those cases where administration of contrast material is compromised by barriers, including embryonic development and the central nervous system,” said Prof. Michal Neeman, from the Weizmann Institute, lead author of the study. The study's findings were published in the February 2005 issue of the journal Neoplasia.



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.